BN80927: A novel homocamptothechin that inhibits proliferation of human tumor cells in vitro and in vivo

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4942-4949

  Demarquay, Danièle ^a   Huchet, Marion ^a   Coulomb, Helène ^a   Lesueur Ginot, Laurence ^a   Lavergne, Olivier ^a   Camara, José ^a   Kasprzyk, Philip G ^b   Prévost, Grégoire ^a   Bigg, Dennis C H ^a  

^a Institut Henri Beaufour   (France)

^b Biomeasure Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BN 80927; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; HOMOCAMPTOTHECIN; IRINOTECAN; LACTONE; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL FREE SYSTEM; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA PROTEIN COMPLEX; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TUMOR CELL; TUMOR CELL LINE; TUMOR RESISTANCE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BLOOD; CELL DIVISION; CELL STRAIN HL 60; CELL STRAIN K 562; DNA SUPERCOILING; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; DRUG STABILITY; ENZYMOLOGY; MALE; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, SUPERHELICAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; K562 CELLS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3142686746     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3872     Document Type: Article

References (42)

1. Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ. An overview of the clinical pharmacology of topotecan. Semin Oncol 1997;24(1 Suppl 5):12-8.
2. Mathijssen RH, Loos WJ, Verweij J, Sparreboom A. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002;2(2): 103-23.
3. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996;52(4): 606-23.
4. Lerchen HG. Milestones in camptothecin research. Drugs Future 2002;27(9):869-78.
5. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000;7:39-58.
6. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1998;1400:195-211.
7. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Bigg DCH. BN 80245: an E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg Med Chem Lett 1997;7:2235-8.
8. Bailly C, Lansiaux A, Dassonneville L et al. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry 1999;38(47):15556-63.
9. Lesueur-Ginot L, Demarquay D, Kiss R et al. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 1999;59(12):2939-43.
10. Bailly C, Laine W, Baldeyrou B et al. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN38. Anticancer Drug Des 2001;16:27-36.
11. Lavergne O, Lesueur-Ginot L, Pla Rodas F et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 1998;41(27):5410-9.
12. Lavergne O, Demarquay D, Bailly C et al. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem 2000;43(11):2285-9.
13. Demarquay D, Huchet M, Coulomb H et al. The homocamptothecin BN80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs 2001;12:9-19.
14. Gelderblom H, Salazar R, Verweij J et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 2003;9(11):4101-7.
15. Lansiaux A, Facompre M, Wattez N et al. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells. Mol Pharmacol 2001;60(3):450-61.
16. Larsen AK, Gilbert C, Chyzak G et al. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 2001;61(7):2961-7.
17. Demarquay D, Coulomb H, Huchet M et al. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Ann N Y Acad Sci 2000;922:301-2.
18. Huchet M, Demarquay D, Coulomb H et al. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci 2000;922:303-5.
19. Lavergne O, Harnett J, Rolland A et al. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg Med Chem Lett 1999;9(17):2599-602.
20. Kingsbury WD, Boehm JC, Jakas DR et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34(1):98-107.
21. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989;49(6): 1465-9.
22. Subramanian D, Rosenstein BS, Muller MT. Ultraviolet-induced DNA damage stimulates topoisomerase I DNA complex formation in vivo: Possible relationship with DNA repair. Cancer Res 1998;58(5):976-84.
23. Singer VL, Jones LJ, Yue ST, Haugland RP. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem. 1997;249:228-38.
24. Skladanowski A, Plisov SY, Konopa J, Larsen AK. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 1996;49:772-80.
25. Taniguchi K, Kohno K, Kawanami K, Wada M, Kanematsu T, Kuwano M. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res 1996;56(10):2348-54.
26. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999;14:169-77.
27. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31(1):13-20.
28. Wagener DJ, Verdonk HE, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995;6(2):129-32.
29. Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003;45(1):91-108.
30. Lansiaux A, Bailly C. A symphony for the camptothecins [in French]. Bull Cancer 2003;90(3):239-45.
31. Mo YY, Beck WT. DNA damage signals induction of fas ligand in tumor cells. Mol Pharmacol 1999;55(2):216-22.
32. Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem 2003;3(3):339-53.
33. Utsugi T, Aoyagi K, Asao T et al. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 1997;88(10):992-1002.
34. Bases RE, Mendez F. Topoisomerase inhibition by lucanthone, an adjuvant in radiation therapy. Int J Radiat Oncol Biol Phys 1997;37(5):1133-7.
35. Etievant C, Kruczynski A, Barret JM et al. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol 2000;46(2):101-13.
36. Perrin D, van Hille B, Barret JM et al. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000;59(7):807-19.
37. Philippart P, Harper L, Chaboteaux C et al. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Clin Cancer Res 2000;6(4):1557-62.
38. Dingemans AM, Pinedo HM, Giaccone G. Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:275-88.
39. Parchment RE, Pessina A. Topoisomerase I inhibitors and drug resistance. Cytotechnology 1998;27:149-64.
40. Ouar Z, Lacave R, Bens M, Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells. Cell Biol Toxicol 1999;15:91-100.
41. Cai JW, Henderson BW, Shen JW, Subjeck JR. Induction of glucose regulated proteins during growth of a murine tumor. J Cell Physiol 1993;154(2):229-37.
42. Shen J, Hughes C, Chao C et al. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 1987; 84(10):3278-82.